Agency Information Collection Activities; Proposed Collection; Comment Request; Records and Reports Concerning Experience With Approved New Animal Drugs; Adverse Event Reports on Forms FDA 1932, 1932a, and 2301, 52967-52968 [E9-24734]
Download as PDF
Federal Register / Vol. 74, No. 198 / Thursday, October 15, 2009 / Notices
Dated: October 7, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–24825 Filed 10–14–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0488]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Records and
Reports Concerning Experience With
Approved New Animal Drugs; Adverse
Event Reports on Forms FDA 1932,
1932a, and 2301
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on DSKH9S0YB1PROD with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
requirements for recordkeeping and
reports concerning experience with
approved new animal drugs. The
information contained in the reports
required by the regulation enables FDA
to monitor the use of new animal drugs
after approval and to ensure their
continued safety and efficacy.
DATES: Submit written or electronic
comments on the collection of
information by December 14, 2009.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley Jr, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3793.
VerDate Nov<24>2008
19:13 Oct 14, 2009
Jkt 220001
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
SUPPLEMENTARY INFORMATION:
Records and Reports Concerning
Experience With Approved New
Animal Drugs; Adverse Event Reports
on Forms FDA 1932, 1932a, and 2301—
21 CFR Section 514.80 (OMB No. 0910–
0284)—Extension
Sections 512(l) of the Federal Food,
Drug, and Cosmetic Act (the act) (21
U.S.C. 360b(l)) and § 514.80 (21 CFR
514.80) of FDA regulations require
applicants of approved new animal drug
applications (NADAs) and abbreviated
new animal drug applications
(ANADAs) to report adverse drug
experiences and product/manufacturing
defects (see § 514.80(b)).
This continuous monitoring of
approved NADAs and ANADAs affords
the primary means by which FDA
obtains information regarding potential
problems with the safety and efficacy of
marketed approved new animal drugs as
well as potential product/manufacturing
problems. Postapproval marketing
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
52967
surveillance is important because data
previously submitted to FDA may not be
adequate, as animal drug effects can
change over time and less apparent
effects may take years to manifest.
Under § 514.80(d), an applicant must
report adverse drug experiences and
product/manufacturing defects on Form
FDA 1932, ‘‘Veterinary Adverse Drug
Reaction, Lack of Effectiveness, Product
Defect Report.’’ Periodic drug
experience reports and special drug
experience reports must be
accompanied by a completed Form FDA
2301, ‘‘Transmittal of Periodic Reports
and Promotional Material for New
Animal Drugs’’ (see § 514.80(d)). Form
FDA 1932a, ‘‘Veterinary Adverse Drug
Reaction, Lack of Effectiveness or
Product Defect Report’’ allows for
voluntary reporting of adverse drug
experiences or product/manufacturing
defects.
The electronic versions of Forms FDA
1932 and 1932a have been incorporated
into the agency-wide information
collection (MedWatchPlus Portal and
Rational Questionnaire) that was
announced for public comment in the
Federal Register of October 23, 2008 (73
FR 63153). MedWatchPlus Portal and
Rational Questionnaire is part of a new
electronic system for collecting,
submitting, and processing adverse
event reports and other safety
information for all FDA-regulated
products. In the Federal Register of May
20, 2009 (74 FR 23721), FDA announced
the submission for OMB review and
clearance of the electronic data
collection using MedWatchPlus Portal
and Rational Questionnaire.
Burden hours for the electronic
versions of these forms were included as
part of the MedWatchPlus Portal and
Rationale Questionnaire information
collection approved under OMB control
number 0910–0645. It is estimated that,
during the first 3 years that the
MedWatchPlus Portal is in use, half of
the reports will be submitted in paper
format and half will be submitted
electronically. In order to avoid double
counting, an estimated 50 percent of
total annual responses for FDA Form
1932 (404) and FDA Form 1932a (81.5)
are counted here as part of OMB control
number 0910–0284 for the paper
versions of Forms FDA 1932 and 1932a,
and an estimated 50 percent of the total
annual responses (404) and (81.5) for
Form FDA 1932 and FDA Form 1932a
respectively, are counted as part of OMB
control number 0910–0645 for the
electronic reporting of these adverse
reports using the MedWatchPlus Portal.
The paper versions of Forms FDA
1932 and 1932a, as well as Form FDA
E:\FR\FM\15OCN1.SGM
15OCN1
52968
Federal Register / Vol. 74, No. 198 / Thursday, October 15, 2009 / Notices
2301, will continue to be counted as
part of OMB control number 0910–0284.
The reporting and recordkeeping
burden estimates, including the total
number of annual responses, are based
on the submission of reports to the
Division of Surveillance, Center for
Veterinary Medicine. The annual
frequency of responses was calculated
as the total annual responses divided by
the number of respondents.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section or Section of
the Act
No. of
Respondents
FDA Form No.
514.80(b)(1), (b)(2)(i),
(b)(2)(ii), and (b)(3)
19322
Voluntary reporting FDA Form
1932a for the public
Annual Frequency
per Response
404
1932a2
44.26
81.5
514.80(b)(4)
2301
2301
84
514.80(b)(5)(ii)
2301
514.80(b)(5)(iii)
2301
Hours per
Response
Total Hours
17,882.5
1
17,882.5
81.5
13
81.5
1
84
514.80(b)(5)(i)
Total Annual
Responses
17.0
1,428
16
22,848
0.31
26
2
52
84
33.92
2,849
2
5,698
646
0.08
49
2
98
Total Hours
46,660
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
hours were determined as explained above.
hours per response for paper versions of Forms FDA 1932 and 1932a are assumed to be 1 hour. The hours per response for the electronic version of Form FDA 1932 is assumed to be 1 hour, while the electronic version of Form FDA 1932a is assumed to take .6 hours to complete the form and gather the required information as part of the MedWatchPlus Portal information collection (see 74 FR 23721 at 23727, May 20,
2009).
2 Burden
3 The
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
21 CFR Section
No. of
Recordkeepers
514.80(e)2
Annual Frequency
per Recordkeeping
646
Total Annual
Records
7.20
Hours per
Record
4651
Total Hours
14
Total
1 There
65,116.8
1,541
are no capital costs or operating and maintenance costs associated with this collection of information.
514.80(e) covers all recordkeeping hours for all adverse event reporting.
2 Section
Dated: October 7, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–24734 Filed 10–14–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
mstockstill on DSKH9S0YB1PROD with NOTICES
Health Disparities Subcommittee,
Advisory Committee to the Director
(ACD), Centers for Disease Control
(CDC); Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned subcommittee.
Time and Date: 2 p.m.–4:30 p.m., October
28, 2009.
Place: The meeting will be convened at the
CDC, 1600 Clifton Road, NE., Atlanta, GA
VerDate Nov<24>2008
19:13 Oct 14, 2009
Jkt 220001
30333, Building 19, Auditorium B1, Global
Communications Center. Please see
Supplementary Information for details on
accessing the meeting location.
Status: Open to the public, limited only by
the availability of space. The meeting room
accommodates approximately 90 people.
Purpose: The Subcommittee will provide
advice to the CDC Director through the
Advisory Committee to the Director on
strategic and other broad issues facing CDC.
Matters To Be Discussed: ACD Health
Disparities Subcommittee 2009 Action
Agenda; CDC Director’s Health Disparity
Indicator Project Update, Director’s Priorities
and Reorganization/Structure.
Agenda items are subject to change as
priorities dictate.
Supplementary Information: To participate
in the meeting, please plan to register with
CDC Security Officials at the Visitor’s Center
at least one hour prior to the meeting. A
government-issued picture ID will be
required. All persons who do not have a
CDC/Health and Human Services
identification will have to be escorted to the
meeting.
Contact Person for More Information:
Walter W. Williams, M.D., M.P.H.,
Designated Federal Officer, Health
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
Disparities Subcommittee, ACD, CDC, 1600
Clifton Road, NE., M/S E–67, Atlanta,
Georgia 30333. Telephone 404/498–2310, Email: https://www1@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: October 8, 2009.
Andre Tyler,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E9–24859 Filed 10–14–09; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\15OCN1.SGM
15OCN1
Agencies
[Federal Register Volume 74, Number 198 (Thursday, October 15, 2009)]
[Notices]
[Pages 52967-52968]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-24734]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0488]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Records and Reports Concerning Experience With
Approved New Animal Drugs; Adverse Event Reports on Forms FDA 1932,
1932a, and 2301
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on requirements for recordkeeping
and reports concerning experience with approved new animal drugs. The
information contained in the reports required by the regulation enables
FDA to monitor the use of new animal drugs after approval and to ensure
their continued safety and efficacy.
DATES: Submit written or electronic comments on the collection of
information by December 14, 2009.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley Jr, Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Records and Reports Concerning Experience With Approved New Animal
Drugs; Adverse Event Reports on Forms FDA 1932, 1932a, and 2301--21 CFR
Section 514.80 (OMB No. 0910-0284)--Extension
Sections 512(l) of the Federal Food, Drug, and Cosmetic Act (the
act) (21 U.S.C. 360b(l)) and Sec. 514.80 (21 CFR 514.80) of FDA
regulations require applicants of approved new animal drug applications
(NADAs) and abbreviated new animal drug applications (ANADAs) to report
adverse drug experiences and product/manufacturing defects (see Sec.
514.80(b)).
This continuous monitoring of approved NADAs and ANADAs affords the
primary means by which FDA obtains information regarding potential
problems with the safety and efficacy of marketed approved new animal
drugs as well as potential product/manufacturing problems. Postapproval
marketing surveillance is important because data previously submitted
to FDA may not be adequate, as animal drug effects can change over time
and less apparent effects may take years to manifest.
Under Sec. 514.80(d), an applicant must report adverse drug
experiences and product/manufacturing defects on Form FDA 1932,
``Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product
Defect Report.'' Periodic drug experience reports and special drug
experience reports must be accompanied by a completed Form FDA 2301,
``Transmittal of Periodic Reports and Promotional Material for New
Animal Drugs'' (see Sec. 514.80(d)). Form FDA 1932a, ``Veterinary
Adverse Drug Reaction, Lack of Effectiveness or Product Defect Report''
allows for voluntary reporting of adverse drug experiences or product/
manufacturing defects.
The electronic versions of Forms FDA 1932 and 1932a have been
incorporated into the agency-wide information collection
(MedWatch\Plus\ Portal and Rational Questionnaire) that was announced
for public comment in the Federal Register of October 23, 2008 (73 FR
63153). MedWatch\Plus\ Portal and Rational Questionnaire is part of a
new electronic system for collecting, submitting, and processing
adverse event reports and other safety information for all FDA-
regulated products. In the Federal Register of May 20, 2009 (74 FR
23721), FDA announced the submission for OMB review and clearance of
the electronic data collection using MedWatch\Plus\ Portal and Rational
Questionnaire.
Burden hours for the electronic versions of these forms were
included as part of the MedWatch\Plus\ Portal and Rationale
Questionnaire information collection approved under OMB control number
0910-0645. It is estimated that, during the first 3 years that the
MedWatch\Plus\ Portal is in use, half of the reports will be submitted
in paper format and half will be submitted electronically. In order to
avoid double counting, an estimated 50 percent of total annual
responses for FDA Form 1932 (404) and FDA Form 1932a (81.5) are counted
here as part of OMB control number 0910-0284 for the paper versions of
Forms FDA 1932 and 1932a, and an estimated 50 percent of the total
annual responses (404) and (81.5) for Form FDA 1932 and FDA Form 1932a
respectively, are counted as part of OMB control number 0910-0645 for
the electronic reporting of these adverse reports using the
MedWatch\Plus\ Portal.
The paper versions of Forms FDA 1932 and 1932a, as well as Form FDA
[[Page 52968]]
2301, will continue to be counted as part of OMB control number 0910-
0284.
The reporting and recordkeeping burden estimates, including the
total number of annual responses, are based on the submission of
reports to the Division of Surveillance, Center for Veterinary
Medicine. The annual frequency of responses was calculated as the total
annual responses divided by the number of respondents.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section or Section of the Act FDA Form No. Respondents per Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
514.80(b)(1), (b)(2)(i), (b)(2)(ii), and (b)(3) 1932\2\ 404 44.26 17,882.5 1 17,882.5
--------------------------------------------------------------------------------------------------------------------------------------------------------
Voluntary reporting FDA Form 1932a for the public 1932a\2\ 81.5 1 81.5 1\3\ 81.5
--------------------------------------------------------------------------------------------------------------------------------------------------------
514.80(b)(4) 2301 84 17.0 1,428 16 22,848
--------------------------------------------------------------------------------------------------------------------------------------------------------
514.80(b)(5)(i) 2301 84 0.31 26 2 52
--------------------------------------------------------------------------------------------------------------------------------------------------------
514.80(b)(5)(ii) 2301 84 33.92 2,849 2 5,698
--------------------------------------------------------------------------------------------------------------------------------------------------------
514.80(b)(5)(iii) 2301 646 0.08 49 2 98
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Hours 46,660
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
\2\ Burden hours were determined as explained above.
\3\ The hours per response for paper versions of Forms FDA 1932 and 1932a are assumed to be 1 hour. The hours per response for the electronic version of
Form FDA 1932 is assumed to be 1 hour, while the electronic version of Form FDA 1932a is assumed to take .6 hours to complete the form and gather the
required information as part of the MedWatch\Plus\ Portal information collection (see 74 FR 23721 at 23727, May 20, 2009).
Table 2.--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
21 CFR No. of Annual Frequency
Section Recordkeepers per Recordkeeping Total Annual Records Hours per Record Total Hours
----------------------------------------------------------------------------------------------------------------
514.80( 646 7.20 4651 14 65,116.8
e)\2\
----------------------------------------------------------------------------------------------------------------
Total 1,541
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ Section 514.80(e) covers all recordkeeping hours for all adverse event reporting.
Dated: October 7, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-24734 Filed 10-14-09; 8:45 am]
BILLING CODE 4160-01-S